Correlations of peripheral blood inflammatory and immune-related indicators with clinicopathological features and prognosis in breast cancer patients

SHI Lihui; ZHANG Teng; LIANG Qiu; MEI Lijuan

doi:10.7619/jcmp.20245649

Journal of Clinical Medicine in Practice > 2025 > 29(6): 75-79. > DOI: 10.7619/jcmp.20245649

SHI Lihui, ZHANG Teng, LIANG Qiu, MEI Lijuan. Correlations of peripheral blood inflammatory and immune-related indicators with clinicopathological features and prognosis in breast cancer patients[J]. Journal of Clinical Medicine in Practice, 2025, 29(6): 75-79. DOI: 10.7619/jcmp.20245649

Citation:

PDF (655 KB)

Correlations of peripheral blood inflammatory and immune-related indicators with clinicopathological features and prognosis in breast cancer patients

Department of Breast Surgery, Maternity and Child Healthcare Hospital of Tongzhou District of Beijing, Beijing, 101100

More Information

Received Date: November 18, 2024
Revised Date: February 15, 2025

Graphical Abstract

Abstract

Abstract

Objective
To investigate correlations of peripheral blood inflammatory and immune-related indices with clinicopathological features and prognosis in breast cancer patients.
Methods
A total of 144 breast cancer patients admitted to the Breast Surgery Department of Maternity and Child Healthcare Hospital of Tongzhou District of Beijing were included in cancer group, 44 patients with atypical breast hyperplasia were included in precancerous lesion group, and 131 patients with breast hyperplasia were included in breast hyperplasia group. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) were compared among the three groups. A three-year follow-up was conducted for prognosis assessment. Based on different NLR, PLR, and LMR levels, the cancer group was divided into low NLR group (< 2.12, 67 patients), high NLR group (≥2.12, 77 patients), low PLR group (< 133.21, 65 patients), high PLR group (≥133.21, 79 patients), low LMR group (< 5.05, 80 patients), and high LMR group (≥5.05, 64 patients). The correlations of NLR, PLR, and LMR with clinicopathological features and prognosis in breast cancer patients were analyzed.
Results
NLR in the cancer group was higher than that in the precancerous lesion group and breast hyperplasia group, the PLR was higher than that in the breast hyperplasia group, and the LMR was lower than that in the breast hyperplasia group (P < 0.05). NLR and PLR in the precancerous lesion group were higher and LMR was lower than those in the breast hyperplasia group (P < 0.05). PLR between patients with different menopausal statuses and Ki-67 levels showed statistically significant differences (P < 0.05). LMR between patients with different menopausal status also showed a statistically significant difference(P < 0.05). After a three-year follow-up, 5 patients in the cancer group had a poor prognosis and 139 had a good prognosis. Poor prognosis rates between the low NLR and high NLR groups, low PLR and high PLR groups, and low LMR and high LMR groups showed statistically significant differences (P < 0.05). Logistic regression analysis
Results
indicated that increased NLR and PLR were risk factors for poor prognosis in cancer patients, while increased LMR was a protective factor.
Conclusion
Peripheral blood inflammatory and immune-related indicators in breast cancer patients exhibit abnormal changes. Increased NLR and PLR are risk factors for poor prognosis, while increased LMR is a protective factor.

FullText(HTML)

References (22)

References

[1]	GARCÍA-GONZÁLEZ D, ROMERO-ELÍAS M, ÁLVAREZ-BUSTOS A, et al. Cancer-related fatigue and circulating biomarkers in breast cancer survivors[J]. Biol Res Nurs, 2024, 26(2): 270-278.
[2]	FARIA S S, GIANNARELLI D, CORDEIRO DE LIMA V C, et al. Development of a prognostic model for early breast cancer integrating neutrophil to lymphocyte ratio and clinical-pathological characteristics[J]. Oncologist, 2024, 29(4): e447-e454.
[3]	INOUE Y, FUJISHIMA M, ONO M, et al. Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer[J]. Breast Cancer Res Treat, 2022, 196(2): 341-348.
[4]	张元浩. 外周血炎症指标在三阴型乳腺癌中的表达及其与临床病理特征的相关性[D]. 河南: 郑州大学, 2023.
[5]	PIVATTO JÙNIOR F, SANTOS Â B S, ENGLERT E F, et al. Monocyte-to-lymphocyte ratio as predictor of cancer therapy-related cardiotoxicity in patients with breast cancer: a pilot cohort study[J]. Breast Cancer Res Treat, 2023, 200(3): 355-362.
[6]	AU A V, SHENCORU S, UHLMANN L, et al. Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer[J]. Arch Gynecol Obstet, 2023, 307(4): 1105-1113.
[7]	孙雨露, 朱婷婷, 姚永忠. 外周血炎症指标对乳腺癌预后评估作用的研究进展[J]. 东南大学学报: 医学版, 2023, 42(6): 960-964. doi: 10.3969/j.issn.1671-6264.2023.06.024
[8]	TOKUNAGA E, MIYOSHI Y, DOZONO K, et al. Association of neutrophil-to-lymphocyte ratio and absolute lymphocyte count with clinical outcomes in advanced breast cancer in the MONARCH 2 trial[J]. Oncologist, 2024, 29(3): e319-e329. doi: 10.1093/oncolo/oyad301
[9]	潘婉婉, 董孟浩, 余发智, 等. 外周血炎症指标NLR、PLR、LMR预测乳腺癌新辅助化疗疗效的价值[J]. 中华全科医学, 2021, 19(9): 1442-1446.
[10]	王坤英, 张蓬杰, 苏兵, 等. 乳腺癌患者血常规及PLR、NLR、LMR特征分析[J]. 检验医学与临床, 2022, 19(1): 84-89.
[11]	GONG Z, XIN R, LI L, et al. Platelet-to-lymphocyte ratio associated with the clinicopathological features and prognostic value of breast cancer: a meta-analysis[J]. Int J Biol Markers, 2022, 37(4): 339-348. doi: 10.1177/03936155221118098
[12]	ZHOU Y, GUO X, SHEN L, et al. Predictive significance of systemic immune-inflammation index in patients with breast cancer: a retrospective cohort study[J]. Onco Targets Ther, 2023, 16: 939-960. doi: 10.2147/OTT.S434193
[13]	WIRA WIGUNA I G W, INDRANI REMITHA N P S, SADVIKA I G A S, et al. Pretreatment leukocyte count ratios as metastatic predictive factors in luminal type breast cancer[J]. Asian Pac J Cancer Prev, 2022, 23(5): 1595-1601. doi: 10.31557/APJCP.2022.23.5.1595
[14]	孔涵. HER-2阳性乳腺癌患者的KI-67表达与新辅助化疗敏感及预后的相关性[D]. 新疆: 新疆医科大学, 2023.
[15]	黄花英, 刘洋, 周莹, 等. TTF-1、Ki67及P63蛋白在非小细胞肺癌中的表达及意义[J]. 检验医学与临床, 2020, 17(20): 2941-2943, 2947. doi: 10.3969/j.issn.1672-9455.2020.20.008
[16]	游会婷, 晋茂生, 刘健. MRI联合CDK4、Ki-67对早期宫颈癌淋巴结转移的预测价值[J]. 中华全科医学, 2024, 22(1): 5-9.
[17]	XIANG Y, ZHANG N, LEI H, et al. Neutrophil-to-lymphocyte ratio is a negative prognostic biomarker for luminal A breast cancer[J]. Gland Surg, 2023, 12(3): 415-425.
[18]	KUSAMA H, KITTAKA N, SOMA A, et al. Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer[J]. Breast Cancer, 2023, 30(6): 1085-1093. doi: 10.1007/s12282-023-01504-y
[19]	边桂风, 李晓东, 贺松, 等. MRI-DWI-IVIM多参数成像对浸润性乳腺癌新辅助化疗后浸润淋巴细胞水平的预测价值[J]. 中华全科医学, 2024, 22(10): 1746-1749.
[20]	谭智慧, 田英慧, 苏雪英, 等. 新辅助化疗联合保乳手术治疗早期乳腺癌的临床疗效及对中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值的影响[J]. 中国临床医生杂志, 2023, 51(6): 699-701. doi: 10.3969/j.issn.2095-8552.2023.06.021
[21]	徐维琳, 周树, 唐金海, 等. 淋巴细胞/单核细胞比值在乳腺癌新辅助化疗疗效评估中的预测价值研究[J]. 中国肿瘤外科杂志, 2023, 15(1): 1-6.
[22]	王慧, 余嘉文, 朱晨, 等. NLR、PLR、LMR与乳腺癌新辅助化疗疗效及预后的关系研究[J]. 现代生物医学进展, 2023, 23(16): 3118-3122.

Cited By

Cited by

Periodical cited type(12)

1.	孙蒙蒙，贾梦，崔博坤. 石决明散对白内障超声乳化患者术后症状评分、泪膜及的眼表变化影响. 四川中医. 2022(06): 175-178 .
2.	张建成. 普拉洛芬滴眼液联合激光周边虹膜切除术治疗急性闭角型青光眼术后感染的疗效观察. 中国合理用药探索. 2022(08): 103-108 .
3.	黄雄飞，张跃红，张柳，高宗银，杨为中. 术前双氯芬酸钠滴眼液联合术后妥布霉素地塞米松滴眼液对家兔白内障术后炎症反应的影响. 中国药师. 2021(01): 64-69 .
4.	赵栋. 妥布霉素地塞米松滴眼液联合普拉洛芬眼液用于控制中老年白内障术后炎性反应的效果. 临床合理用药杂志. 2021(08): 143-144 .
5.	王博，王世娟. 重组人表皮生长因子联合玻璃酸钠滴眼液在白内障术后干眼中的应用. 河南医学研究. 2021(07): 1272-1274 .
6.	高世凯，李海波. 普拉洛芬滴眼液治疗白内障术后炎症的有效性分析. 中国当代医药. 2021(11): 158-161 .
7.	林浓浓，李岚，晏芳，黄瑞华. 耳穴压豆在白内障摘除术患者中的应用观察. 基层医学论坛. 2021(29): 4240-4241 .
8.	岑爱丽，黄丽萍，谢艳兰，吴伟，周小艺，严洁，潘姗姗，陆文玲. 改良眼镜用于白内障手术患者辅助自滴眼液. 护理学杂志. 2020(10): 38-39 .
9.	王家玲. 普拉洛芬滴眼液对维持白内障术中瞳孔大小的作用. 吉林医学. 2020(06): 1347-1348 .
10.	温向国. 妥布霉素地塞米松联合普拉洛芬滴眼液对白内障术后炎症反应及康复的影响. 世界复合医学. 2020(11): 169-171 .
11.	徐浩杰. 普拉洛芬联合氯替泼诺治疗白内障患者术后炎症效果研究. 人人健康. 2019(12): 236 .
12.	王美玲，孙彦敏. 普拉洛芬滴眼液对白内障患者超乳术后炎症临床效果分析. 中外医疗. 2019(23): 11-13 .

Other cited types(0)

Get Citation

PDF

XML

Article views (21) PDF downloads (4) Cited by(12)

Turn off MathJax

Article Contents

Abstract

References

Correlations of peripheral blood inflammatory and immune-related indicators with clinicopathological features and prognosis in breast cancer patients

Abstract

References

Cited by

Periodical cited type(12)

Other cited types(0)

Catalog

Export File

Citation

Format

Content